Access Restriction

Author Lin, Qiaoya ♦ Jin, Cheng S. ♦ Huang, Huang ♦ Ding, Lili ♦ Zhang, Zhihong ♦ Chen, Juan ♦ Zheng, Gang
Source World Health Organization (WHO)-Global Index Medicus
Content type Text
Publisher Wiley-VCH
File Format HTM / HTML
Language English
Difficulty Level Medium
Subject Domain (in DDC) Natural sciences & mathematics ♦ Chemistry & allied sciences ♦ Life sciences; biology ♦ Physiology & related subjects ♦ Biochemistry ♦ Genetics and evolution ♦ Natural history of organisms ♦ Technology ♦ Medicine & health ♦ Human anatomy, cytology, histology ♦ Human physiology ♦ Pharmacology and therapeutics ♦ Diseases ♦ Manufacture for specific uses ♦ Precision instruments & other devices
Subject Domain (in MeSH) Cells ♦ Anatomy ♦ Eukaryota ♦ Organisms ♦ Neoplasms ♦ Diseases ♦ Nucleic Acids, Nucleotides, and Nucleosides ♦ Biomedical and Dental Materials ♦ Pharmaceutical Preparations ♦ Chemicals and Drugs ♦ Diagnosis ♦ Therapeutics ♦ Analytical, Diagnostic and Therapeutic Techniques and Equipment ♦ Chemical Phenomena ♦ Genetic Phenomena ♦ Physiological Phenomena ♦ Biological Sciences
Subject Keyword Discipline Nanotechnology ♦ Drug Monitoring ♦ Methods ♦ Genetic Therapy ♦ Nanocapsules ♦ Prostatic Neoplasms ♦ Pathology ♦ Therapy ♦ Rna, Small Interfering ♦ Administration & Dosage ♦ Animals ♦ Cell Line, Tumor ♦ Dose-response Relationship, Drug ♦ Gene Silencing ♦ Liposomes ♦ Chemistry ♦ Male ♦ Mice ♦ Microscopy, Fluorescence ♦ Ultrastructure ♦ Particle Size ♦ Genetics ♦ Journal Article ♦ Research Support, Non-u.s. Gov't
Abstract The abilities to deliver siRNA to its intended action site and assess the delivery efficiency are challenges for current RNAi therapy, where effective siRNA delivery will join force with patient genetic profiling to achieve optimal treatment outcome. Imaging could become a critical enabler to maximize RNAi efficacy in the context of tracking siRNA delivery, rational dosimetry and treatment planning. Several imaging modalities have been used to visualize nanoparticle-based siRNA delivery but rarely did they guide treatment planning. We report a multimodal theranostic lipid-nanoparticle, HPPS(NIR)-chol-siRNA, which has a near-infrared (NIR) fluorescent core, enveloped by phospholipid monolayer, intercalated with siRNA payloads, and constrained by apoA-I mimetic peptides to give ultra-small particle size (<30 nm). Using fluorescence imaging, we demonstrated its cytosolic delivery capability for both NIR-core and dye-labeled siRNAs and its structural integrity in mice through intravenous administration, validating the usefulness of NIR-core as imaging surrogate for non-labeled therapeutic siRNAs. Next, we validated the targeting specificity of HPPS(NIR)-chol-siRNA to orthotopic tumor using sequential four-steps (in vivo, in situ, ex vivo and frozen-tissue) fluorescence imaging. The image co-registration of computed tomography and fluorescence molecular tomography enabled non-invasive assessment and treatment planning of siRNA delivery into the orthotopic tumor, achieving efficacious RNAi therapy.
Description Country affiliation: China
Author Affiliation: Lin Q ( Princess Margaret Cancer Center and Techna Institute, UHN, TMDT 5-362, 101 College Street, Toronto, ON, M5G 1L7, Canada)
ISSN 16136810
Educational Role Student ♦ Teacher
Age Range above 22 year
Educational Use Reading ♦ Research ♦ Self Learning
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2014-08-13
Publisher Place Germany
e-ISSN 16136829
Journal Small
Volume Number 10
Issue Number 15

Source: WHO-Global Index Medicus